Company
Novartis
Novartis has 101 drugs tracked on RxWires: 17 post-market, 9 approved, 25 in Phase 3, 1 in Phase 2/3, 27 in Phase 2, 5 in Phase 1/2, 17 in Phase 1.
- Ticker
- NVS
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Everolimus | Post-Market | Transplantation Infection |
| Secukinumab s.c. injection | Post-Market | Autoimmunity, Inflammation |
| Ruxolitinib | Post-Market | Steroid-refractory Acute Graft Versus Host Disease |
| Fingolimod | Post-Market | Multiple Sclerosis |
| Asciminib single agent | Post-Market | Chronic Myelogenous Leukemia |
| Egaten (Triclabendazole) 250 mg tablets | Post-Market | Fascioliasis |
| Ranibizumab | Post-Market | Diabetic Retinopathy |
| Tick-Borne Encephalitis vaccine | Post-Market | Encephalitis, Tick-Borne |
| Secukinumab 300 mg | Post-Market | Chronic Plaque Psoriasis |
| zoledronic acid | Post-Market | Non-Small-Cell Lung Cancer |
| Carbidopa/levodopa/entacapone | Post-Market | Parkinson's Disease |
| Formoterol fumerate | Post-Market | Acute Bronchial Obstruction, Asthma |
| FTY720 | Post-Market | Multiple Sclerosis |
| Exelon (rivastigmine) | Post-Market | Cognitive Impairment |
| Imatinib Mesylate | Post-Market | Gastrointestinal Stromal Tumors |
| Combination of pimecrolimus and fluticasone | Post-Market | Atopic Dermatitis |
| dabrafenib | Post-Market | Melanoma |
| LESCOL | Approved | |
| APRESOLINE-ESIDRIX | Approved | |
| GENTACIDIN | Approved | |
| TOFRANIL | Approved | |
| VOLTAREN | Approved | |
| ESIDRIX | Approved | |
| AMTURNIDE | Approved | |
| DIOVAN | Approved | |
| ACYLANID | Approved | |
| placebo | Phase 3 | Acute Blunt Soft Tissue Injuries/Contusions |
| Aliskiren | Phase 3 | Hypertension |
| Intravitreal ranibizumab | Phase 3 | Glaucoma, Neovascular |
| Brolucizumab 6 mg | Phase 3 | Age-related Macular Degeneration |
| Remibrutinib | Phase 3 | Chronic Pruritus of Unknown Origin |
| Ianalumab | Phase 3 | Systemic Lupus Erythematosus |
| VAY736 | Phase 3 | Sjögren´s Disease |
| Drug: Atrasentan | Phase 3 | Berger Disease |
| Pelabresib | Phase 3 | Primary Myelofibrosis (PMF) |
| JDQ443 | Phase 3 | Non-Small Cell Lung Cancer |
| iptacopan | Phase 3 | C3G |
| 177Lu-PSMA-617 | Phase 3 | Prostatic Neoplasms |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Phase 3 | Primary Prevention of Atherosclerotic Cardiovascular Disease |
| KLU156 | Phase 3 | Uncomplicated Plasmodium Falciparum Malaria |
| LNP023 | Phase 3 | IgA Nephropathy |
| QVM149 | Phase 3 | Asthma |
| Omalizumab | Phase 3 | Chronic Spontaneous Uriticaria |
| Tobramycin inhalation powder | Phase 3 | Pulmonary Infections |
| Seasonal Influenza Vaccine | Phase 3 | Seasonal Influenza, Vaccine |
| Ribociclib | Phase 3 | Early Breast Cancer |
| Novartis Investigational H5N1 vaccine | Phase 3 | Influenza, Human |
| Agomelatine (AGO178C) | Phase 3 | Major Depressive Disorder |
| QMF149 | Phase 3 | Asthma |
| Crizanlizumab | Phase 3 | Sickle Cell Disease |
| Pelacarsen | Phase 3 | Hyperlipoproteinemia (a) |
| ensovibep | Phase 2/3 | COVID-19 |
| Dovitinib | Phase 2 | Clear Cell Renal Cell Carcinoma |
| FWY003 | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration |
| GIA632 | Phase 2 | Cutaneous Lichen Planus |
| Arumakimig | Phase 2 | VEXAS Syndrome |
| DDY391 | Phase 2 | Moderate to Severe Psoriatic Arthritis |
| MAS825 | Phase 2 | Still´s Disease |
| AAA617 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| VHB937 | Phase 2 | Alzheimer's Disease |
| pimecrolimus and clobetasol | Phase 2 | Lichen Sclerosus |
| capmatinib | Phase 2 | Non-small Cell Lung Cancer |
| hydroxyurea | Phase 2 | Glioblastoma |
| LYS228 | Phase 2 | Intra-abdominal Infections |
| Letrozole | Phase 2 | Postmenopausal Women With Advanced Breast Cancer |
| ACZ885 | Phase 2 | Sickle Cell Anemia |
| MenABCWY | Phase 2 | Meningococcal Disease |
| bimagrumab | Phase 2 | Sarcopenia |
| AAE581 | Phase 2 | Osteoporosis |
| LCZ696 | Phase 2 | Hypertension |
| QVM149 150/50/80 μg o.d. | Phase 2 | Asthma |
| AQW051 2 mg (single and multiple doses) | Phase 2 | Schizophrenia Disorders |
| Alpelisib | Phase 2 | PIK3CA-related Overgrowth Spectrum (PROS) |
| Glycopyrronium bromide 25ug | Phase 2 | Asthma |
| LOU064 | Phase 2 | Papulopustular Rosacea |
| EYU688 | Phase 2 | Dengue |
| JSB462 | Phase 2 | Metastatic Hormone-sensitive Prostate Cancer |
| EDI048 | Phase 2 | Cryptosporidiosis |
| LXE408 | Phase 2 | Chagas Disease |
| Asciminib Pediatric formulation group | Phase 1/2 | Myeloid Leukemia, Philadelphia Positive |
| Iloperidone crystalline formulation | Phase 1/2 | Schizophrenia |
| LEE011 | Phase 1/2 | Breast Cancer |
| MBG453 | Phase 1/2 | Advanced Malignancies |
| VAY736 lower dose | Phase 1/2 | Primary Sjögren's Syndrome |
| XEP527 | Phase 1 | Schizophrenia |
| DKB903 | Phase 1 | Rheumatoid Arthritis and Systemic Lupus Erythematosus |
| EGF816 | Phase 1 | EGFR-mutant Non-small Cell Lung Cancer |
| Part 1; LOU064 (Remibrutinib) | Phase 1 | Hepatic Impairment |
| PKN605 | Phase 1 | |
| Binimetinib | Phase 1 | Recurrent Non-Small Cell Lung Carcinoma |
| LNA043 | Phase 1 | Osteoarthritis |
| LTT462 | Phase 1 | Ovarian Neoplasms |
| KFA115 | Phase 1 | Carcinoma, Non-Small-Cell Lung |
| DKY709 | Phase 1 | Carcinoma, Non-Small-Cell Lung |
| LBH589 | Phase 1 | Carcinoma, Non-Small-Cell Lung |
| Ganaplacide | Phase 1 | Malaria |
| AGO178 | Phase 1 | Hepatic Impairment |
| EPO906 (patupilone) | Phase 1 | Colon Cancer |
| DCY636 | Phase 1 | Dermatitis, Atopic |
| OJR520 | Phase 1 | Chronic Kidney Disease |
Latest
- Alpelisib moved to Phase 2
- Ribociclib moved to Phase 3
- Dabrafenib moved to Post-Market
- Ruxolitinib moved to Post-Market
- Ianalumab moved to Phase 3
Follow Novartis on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.